Viewing Study NCT03872427

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:12 AM
Ignite Modification Date: 2025-12-26 @ 4:17 AM
Study NCT ID: NCT03872427
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-14
First Post: 2019-03-12
Is NOT Gene Therapy: False
Has Adverse Events: True
Brief Title: Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Malignant Solid Neoplasm View
None Metastatic Malignant Solid Neoplasm View
None NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor View
None Unresectable Malignant Solid Neoplasm View
Keywords: